| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 13, 2002
Accepted on December 11, 2002
and Essential for the Antiproliferative Activity of ICI 182,780 in ER
-Positive Breast Cancer Cells
1 Medical Sciences, Indiana University School of Medicine, Bloomington IN 47405; Department of Obstetrics & Gynecology, Department of Cellular and Integrative Physiology, Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202
* To whom correspondence should be addressed. E-mail: knephew{at}indiana.edu.
Steroid hormone receptors, including estrogen receptor-alpha (ER
), are ligand activated transcription factors, and hormone binding leads to depletion of receptor levels via proteasome-mediated degradation. NEDD8 is an ubiquitin-like protein essential for protein processing and cell cycle progression. We recently demonstrated that Uba3, the catalytic subunit of the NEDD8-activating enzyme, inhibits ER
transcriptional activity. Here we report that Uba3-mediated inhibition of ER
transactivation function is due to increased receptor protein turnover. Coexpression of Uba3 with ER
increased receptor degradation by the 26S proteasome. Inhibition of NEDD8 activation and conjugation diminished polyubiquitination of ER
and blocked proteasome-mediated degradation of receptor protein. The antiestrogen, ICI 182,780 is known to induce ER degradation. In human MCF7 breast cancer cells modified to contain a disrupted NEDD8 pathway, ICI 182,780-degradation of ER
was impaired, and the antiestrogen was ineffective at inhibiting cell proliferation. This study provides the first evidence linking nuclear receptor degradation with the NEDD8 pathway and the ubiquitin-proteasome system, suggesting that the two pathways can act together to modulate ER
turnover and cellular responses to estrogens. Based on our observation that an intact NEDD8 pathway is essential for the antiproliferation activity of the ICI 182,780 in ER
positive breast cancer cells, we propose that disruptions in the NEDD8 pathway provide a mechanism by which breast cancer cells acquire antiestrogen resistance while retaining expression of ER
.
NURSA Molecule Pages Link:
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |